Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
Hypertrophic cardiomyopathy (HCM) affects more than 1 in 500 people in the general population with an extensive burden of morbidity in the form of arrhythmia, heart failure, and sudden death. More than 25 years since the discovery of the genetic underpinnings of HCM, the field has unveiled significa...
Main Authors: | Masataka Kawana, James A. Spudich, Kathleen M. Ruppel |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2022.975076/full |
Similar Items
-
Erratum: Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
by: Frontiers Production Office
Published: (2022-12-01) -
Familial Hypertrophic Cardiomyopathy: Diagnosis and Management
by: Litt MJ, et al.
Published: (2023-04-01) -
Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
by: Ahmad Masri, et al.
Published: (2022-05-01) -
To lie or not to lie: Super-relaxing with myosins
by: Suman Nag, et al.
Published: (2021-02-01) -
Prospects for remodeling the hypertrophic heart with myosin modulators
by: Lorenzo R. Sewanan, et al.
Published: (2022-10-01)